Discordance between ischemia and stenosis, or PINSS and NIPSS: Are we ready for new vocabulary?

JACC: Cardiovascular Imaging

Volumn 8, Issue 1, 2015, Pages 111-114

  Ahmadi, Amir ^a   Kini, Annapoorna ^a   Narula, Jagat ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary stenosis; Endothelial dysfunction; Fractional flow reserve; Lipid rich plaques; Myocardial ischemia; Oxidative stress

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ISOPROSTANE DERIVATIVE; MYELOPEROXIDASE; NITRIC OXIDE; PEROXYNITRITE; SUPEROXIDE DISMUTASE;

ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FRACTIONAL FLOW RESERVE; HEART MUSCLE ISCHEMIA; HUMAN; MYOCARDIAL PERFUSION IMAGING; OXIDATIVE STRESS; OXYGEN SUPPLY; PRIORITY JOURNAL; REVIEW; ISCHEMIA; PATHOLOGY; PATHOPHYSIOLOGY; STENOSIS, OCCLUSION AND OBSTRUCTION; VASCULAR ENDOTHELIUM;

CONSTRICTION, PATHOLOGIC; ENDOTHELIUM, VASCULAR; HUMANS; ISCHEMIA; MYOCARDIAL ISCHEMIA; PLAQUE, ATHEROSCLEROTIC;

EID: 84922574348     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2014.11.010     Document Type: Editorial

References (31)

1. Park HB, Heo R, ó Hartaigh B, et al. Atherosclerotic plaque characteristics by CT angiography identify coronary lesions that cause ischemia: a direct comparison to fractional flow reserve. J Am Coll Cardiol Img 2015;8:1-10.
2. Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007;50:319-26.
3. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009;54:49-57.
4. Shmilovich H, Cheng VY, Tamarappoo BK, et al. Vulnerable plaque features on coronary CT angiography as markers of inducible regional myocardial hypoperfusion from severe coronary artery stenoses. Atherosclerosis 2011;219:588-95.
5. Nakazato R, Shalev A, Doh JH, et al. Aggregate plaque volume by coronary computed tomography angiography is superior and incremental to luminal narrowing for diagnosis of ischemic lesions of intermediate stenosis severity. J Am Coll Cardiol 2013;62:460-7.
6. Gould KL, Lipscomb K, Calvert C. Compensatory changes of the distal coronary vascular bed during progressive coronary constriction. Circulation 1975;51:1085-94.
7. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91.
8. Park SJ, Kang SJ, Ahn JM, et al. Visualfunctional mismatch between coronary angiography and fractional flow reserve. J Am Coll Cardiol Intv 2012;5:1029-36.
9. Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010;55:2816-21.
10. Lavi S, Bae JH, Rihal CS, et al. Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart 2009;95:1525-30.
11. Lavi S, McConnell JP, Rihal CS, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115: 2715-21.
12. Lavi S, Yang EH, Prasad A, et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 2008;51:127-33.
13. Lerman A, Holmes DR Jr., Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426-31.
14. Gokce N, Keaney JF Jr., Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72.
15. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, thrombosis, and vascular biology 2003;23:168-75.
16. van't Hoen PA, Van der Lans CA, Van Eck M, Bijsterbosch MK, Van Berkel TJ, Twisk J. Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res 2003;93:262-9.
17. Palinski W. United they go: conjunct regulation of aortic antioxidant enzymes during atherogenesis. Circ Res 2003;93:183-5.
18. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000;275:37524-32.
19. Wilson SH, Best PJ, Lerman LO, Holmes DR Jr., Richardson DM, Lerman A. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2 alpha, in experimental hypercholesterolemia. Cardiovasc Res 1999;44: 601-7.
20. Krier JD, Rodriguez-Porcel M, Best PJ, Romero JC, Lerman A, Lerman LO. Vascular responses in vivo to 8-epi PGF(2alpha) in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol 2002;283:R303-8.
21. Mehrabi MR, Ekmekcioglu C, Tatzber F, et al. The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 1999; 43:492-9.
22. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013;34: 719-28.
23. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:2909-17.
24. Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006;26:106-11.
25. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47:C19-31.
26. Inoue N, Takeshita S, Gao D, et al. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 2001;155:45-52.
27. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006;12:RA5-16.
28. Safaya R, Chai H, Kougias P, et al. Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J Surg Res 2005;126: 182-8.
29. Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 2013;61:1041-51.
30. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003;108:1664-72.
31. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226-35.